In a report released yesterday, Sumant Kulkarni from Canaccord Genuity maintained a Buy rating on Intra-Cellular Therapies (ITCI – Research Report), with a price target of $70.00. The company’s shares closed last Monday at $19.46. According to TipRanks.com, Kulkarni is